Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Warning On Ocaliva Puts Intercept's NASH Opportunity In Jeopardy

Sep 22 2017

• By Emily Hayes

RubberStampWarning_1200x675

Related Content

Intercept's Revised NASH Trial Improves Prospects

Feb 13 2017

'Clean Label' For Intercept's Ocaliva In PBC Bodes Well For NASH Claim

Jun 06 2016

Related Companies

Intercept Pharmaceuticals, Inc.

Genfit SA

Gilead Sciences, Inc.

Allergan plc

Additional Topics

Drug Safety FDA Regulation Liver & Hepatic BioPharmaceutical

More from Alimentary/Metabolic

More from Therapeutic Category

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.